The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Somatostatin receptor antagonists for imaging and therapy.
Open accessAbstract
Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have been used for more than 20 y. An important improvement in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled sstr agonists, such as [90Y-DOTA0,Tyr3]octreotide or [177Lu-DOTA0,Tyr3]octreotide (90Y- or 177Lu-DOTATOC, respectively) and [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE). PET/CT with 68Ga-labeled sstr agonists, such as 68Ga-DOTATOC, 68Ga-DOTATATE, and [68Ga-DOTA,1-Nal3]octreotide (68Ga-DOTANOC), plays an important role in staging and restaging neuroendocrine tumors. Most importantly, sstr scintigraphy and sstr PET/CT can distinguish patients who will qualify for and benefit from peptide receptor radionuclide therapy. This characteristic of sstr targeting is important because it allows a personalized treatment approach (theranostic approach). Until recently, it was thought that internalization of the radiolabeled agonist was mandatory for sstr-mediated imaging and therapy. It was Ginj et al. who proposed in 2006 the paradigm shift that radiolabeled sstr antagonists may perform better than agonists despite the lack of internalization. Despite the rather limited number of head-to-head comparisons of sstr antagonists and agonists, the superiority of sstr antagonists was demonstrated in several cases. From a small library of sstr antagonists, the analog JR11 (Cpa-c[d-Cys-Aph(Hor)-d-Aph(Cbm)-Lys-Thr-Cys]-d-Tyr-NH2), an antagonist with selectivity for sstr subtype 2, showed the best overall characteristics for sstr subtype 2 targeting and was therefore selected for clinical translation. JR11 is under clinical development as a PET imaging agent when labeled with 68Ga (68Ga-NODAGA-JR11 or 68Ga-OPS202) and as a therapeutic agent when labeled with 177Lu (177Lu-DOTA-JR11 or 177Lu-OPS201). In this article, we discuss the development and current status of radiolabeled sstr antagonists. Evidence based on preclinical work, on quantitative in vivo autoradiography of human tumor slices, and on human data now supports a shift to sstr antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Taking the proposed mechanism, preclinical and clinical studies into consideration, it is obvious that using radiolabeled SSTR antagonists, especially LM3 and JR11, may provide more successful imaging and PRRT strategies for neuroendocrine tumors, even those with relatively low SSTR expression (130, 137, 141) compared to agonists.”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Pavel, M. E., O’Toole, D., Costa, F. P., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E. P., Knigge, U., Salazar, R., Pape, U., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,038
Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Érchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607761103 · Cited by 526
Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R. P., Reubi, J. C., & Maëcke, H. R. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0317-x · Cited by 395
Wild, D., Fani, M., Fischer, R., Pozzo, L. D., Kaul, F., Krebs, S. S., Fischer, R., Rivier, J., Reubi, J. C., Maëcke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 267
Fani, M., Pozzo, L. D., Abiraj, K., Mansi, R., Tamma, M. L., Cescato, R., Waser, B., Weber, W., Reubi, J. C., & Maëcke, H. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.087999 · Cited by 264
Radiopeptide Imaging and Therapy in Europe
Ambrosini, V., Fani, M., Fanti, S., Forrer, F., & Maëcke, H. R. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.085753 · Cited by 201
First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible
Wild, D., Fani, M., Béhé, M. P., Brink, I., Rivier, J., Reubi, J. C., Maëcke, H. R., & Weber, W. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.088922 · Cited by 184
Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications
Fani, M., Braun, F., Waser, B., Beetschen, K., Cescato, R., Erchegyi, J., Rivier, J. E., Weber, W. A., Maecke, H. R., & Reubi, J. C. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.102764 · Cited by 172
Self-citation
Flagged first, then by citations
1 of the 24 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Nicolas, 2015, Wider safety window with radiolabeled somatostatin receptor antagonists over agonists [abstract], J Nucl Med., 56, 335
Cited by
Sorted by citations
Items 201–274 of 274
Makris, G., Li, Y., Gallazzi, F., Kuchuk, M., Wang, J., Lewis, M. R., Jurisson, S. S., & Hennkens, H. M. (2023) · Radiochimica Acta · doi:10.1515/ract-2022-0097 · Cited by 2
Radiopharmaceuticals for molecular imaging and theranostics of glioblastoma
Pinto, C. I. G., Guerreiro, J. F., Silva, F., Mendes, F., & Paulo, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99873-4.00023-2 · Cited by 3
Dosimetric analysis of a compartmental model for radioligand uptake in tumor lesions
Galler, M., Chibolela, C., Rogasch, J. M. M., Huang, K., Siefert, J., Schatka, I., & Amthauer, H. (2023) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ace44a · Cited by 2
Wongso, H. (2019) · Indonesian Journal of Cancer Chemoprevention · doi:10.14499/indonesianjcanchemoprev10iss2pp101-113 · Cited by 2
Allen, K. J. H., Jiao, R., Malo, M. E., & Dadachova, E. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2480 · Cited by 2
Hade, A. B., Kadam, S. M., & Essa, S. I. (2023) · East European Journal of Physics · doi:10.26565/2312-4334-2023-2-31 · Cited by 2
Ferreira, V. F. C., Oliveira, B. L., Santos, J. D., Correia, J. D. G., Farinha, C. M., & Mendes, F. (2018) · ChemMedChem · doi:10.1002/cmdc.201800187 · Cited by 2
Furman, B. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.97143-5 · Cited by 1
Wild, D., & Fani, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_16 · Cited by 1
Soni, U., Thorat, V. G., & Pujari, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34199-1.00013-2 · Cited by 1
Head-to-Head Comparison of [ 68 Ga]Ga-DOTATATE PET/CT and [ 68 Ga]Ga-NODAGA-LM3 PET/CT
Canan, C. A. N., Kömek, H., Güzel, Y., Akdeniz, N., Karaoğlan, H., Kaplan, İ., Güzel, F., Yeprem, Ö., Akyıldız, E., & Kepenek, F. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271074 · Cited by 1
Therapy for aggressive pituitary tumors and carcinomas
Ilie, M. D., Lamback, E. B., Gadelha, M. R., & Raverot, G. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10039-4 · Cited by 1
Theranostics and Molecular-targeted Endo-radiotherapy: The Current Landscape and Future Directions
Nazar, A. K., & Basu, S. K. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006120 · Cited by 1
Gabriel, M. (2018) · Journal für Klinische Endokrinologie und Stoffwechsel · doi:10.1007/s41969-018-0034-7 · Cited by 1
Radionuclide imaging of neuroendocrine tumors
Petrović, J., Μacut, D., & Sobic-Saranovic, D. P. (2020) · Medicinski podmladak · doi:10.5937/mp71-27009 · Cited by 1
Morgan, K. A., & Donnelly, P. S. (2021) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2021.05.002 · Cited by 1
Mohnike, W., Mohnike, K., Lampe, M., & Hildebrandt, S. (2024) · Springer eBooks · doi:10.1007/978-3-662-67192-4_32 · Cited by 1
Ji, A., & Cheng, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95223-1.00014-x · Cited by 1
Ballal, S., Sheokand, P., Yadav, M. P., Roesch, F., Viswanathan, R., Satapathy, S., Tripathi, M., Moon, E. S., Mishra, P., Rastogi, S., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005649 · Cited by 1
Yang, F., Zhan, Y., Luo, F., Cao, L., Chen, F., Zhang, H., Li, S., & Xu, H. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-025-10323-8 · Cited by 1
Training Requirements for Theranostics: A Unique Opportunity for Collaboration
Graham, M. M., & Buatti, J. M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.228940 · Cited by 1
Biochemical basics of imaging in positron emission tomography in oncology. Part 2
Leontyev, A. V., Рубцова, Н. А., Khalimon, A. I., Khamadeeva, G. F., Кулиев, М. Т., Pylova, I. V., Лазутина, Т. Н., Kostin, A. A., & Каприн, А. Д. (2020) · Medical Visualization · doi:10.24835/1607-0763-2020-1-119-132 · Cited by 1
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
DaSilva, J. N., Decristoforo, C., Mach, R. H., Bormans, G. M., Carlucci, G., Al-Qahtani, M., Duatti, A., Gee, A. D., Szymański, W., Rubow, S. M., et al. (2023) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-023-00218-y · Cited by 1
Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
Forrer, F. (2019) · Springer eBooks · doi:10.1007/978-3-030-17494-1_4
Novel strategies for targeted therapy in NETs
Jin, X. (2019) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.24484
Recent Advances in quantitative dynamic PET imaging of neuroendocrine tumors
Fu, P., Zheng, C., & Zhou, Y. (2020) · Medical Research Archives · doi:10.18103/mra.v8i9.2202
Stanzhevsky, A. A., Mosunov, A. A., Чипига, Л. А., Водоватов, А. В., Naurzbaeva, L. T., Kushnarenko, S. M., Lavreshov, D. D., & Petrova, A. E. (2020) · Pharmacy Formulas · doi:10.17816/phf52958
A journey of skull base chordoma
Santegoeds, R. G. C. (2021) · doi:10.26481/dis.20210603rs
[111In-DTPA0-D-Phe1]-Octreotide: The Ligand—The Receptor—The Label
Zanglis, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-70773-6_4
In vitro studies with radiopharmaceuticals
Decristoforo, C., & Pfister, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00012-0
PET Imaging in Neuro-Endocrine Neoplasms (NEN)
Fanti, S., & Ambrosini, V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00034-x
Peptidradiorezeptor-Therapie (PRRT)
Buck, A. K., Lapa, C., Weich, A., Higuchi, T., Hasenauer, N., Hänscheid, H., & Werner, R. A. (2021) · Der Nuklearmediziner · doi:10.1055/a-1556-8323
Cylindrical Lenses Based Spectral Domain Low-Coherence Interferometry for On-line Surface Inspection
Tang, D., Gao, F., & Jiang, X. (2014) · University of Huddersfield Repository (University of Huddersfield)
Modern hybrid imaging of neuroendocrine tumors (clinical lecture)
Korol, P. O., & Ivakh, M. O. (2021) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.4.2021.108-118
Mathur, Y., Krishnaraju, V. S., Singh, H., Kumar, R., & Dutta, P. (2022) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004116
Peptide radiopharmaceuticals for targeted diagnosis & therapy of human tumors
Μάινα, Θ., & Nock, B. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822960-6.00078-8
Μάινα, Θ., & Thakur, M. L. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00023-5
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_303-1
Design of Radiolabeled Peptide Radiopharmaceuticals
Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_20
Theranostics in Neuroendocrine Tumors
Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_21
Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_14
Thakur, S., Daley, B., Millo, C., Cochran, C. S., Jacobson, O., Lu, H., Wang, Z., Kiesewetter, D. O., Chen, X. S., Vasko, V. V., et al. (2023) · doi:10.1158/1078-0432.c.6530313
Pharmacometric approaches to improve theranostics
Siebinga, H. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1920
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapy
Stasio, G. D. D., Farulla, L. S. A., Botta, F., Gilardi, L., & Grana, C. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_14
Diagnosis and therapy of pancreatic NEN using peptide receptor radioligands
Hosono, M. (2023) · Suizo · doi:10.2958/suizo.38.375
Nock, B. A., & Μάινα, Θ. (2024) · Springer eBooks · doi:10.1007/978-3-031-33533-4_22
Technological evolution in cancer diagnosis and therapeutics
Mishra, M., Tyagi, B., Taimoor, N., & Bose, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95116-6.00018-9
Stellenwert der Peptid-Radio-Rezeptor-Therapie für das Management neuroendokriner Tumoren
Ciuciulkaite, I., Herrmann, K., & Lahner, H. (2024) · Die Onkologie · doi:10.1007/s00761-024-01597-w
Novel radiopharmaceuticals in endocrinology: a comprehensive review
Pocięgiel, M., Saniewski, T., Wrzosek, K., Opyd, P., Franek, E., & Lis, M. (2024) · Endokrynologia Polska · doi:10.5603/ep.99756
Automated Production of 64cu-Nota-Jr11 on a Medical Cyclotron and Imaging on Micro-Pet/CtPreprint
Yang, F., zhan, Y., Cao, L., Chen, F., Zhang, H., Li, S., & Xu, H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5061546
Advances with radiopharmaceutical therapy in cancer
Lepareur, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00002-9
Speicher, T., Burgard, C., Rosar, F., Bastian, M. B., Bartholomä, M. D., Maus, S., & Ezziddin, S. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005936
Neuroendocrine Tumors: Radiopharmaceuticals for Imaging and Therapy
Sharma, P., & Singh, S. S. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00309
Optimized Automated Cassette-Based Synthesis of [68Ga]Ga-DOTATOC
Hörmann, A. A., Neumann, J., Nadeje, S., Schweighofer-Zwink, G., Rendl, G., Jung, T., Kiener, T. A., Lechner, R., Friedl, S., Huber-Schönauer, U., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091274
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_303
Luminescent and photofunctional transition metal complexes for targeted cancer phototheranostics
Lee, L. C.-C., & Lo, K. K. (2025) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2025.09.004
Theranostics in surgical oncology
Stättner, S., Søreide, K., Hallet, J. I., Grana, C. M., Partelli, S., Herrmann, K., & Brandl, A. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.111187
Xia, Y., Zeng, C., Zhao, Y., Zhang, X., Li, Z., & Chen, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12135255
Meester, E. J., de Blois, E., Krenning, B. J., van der Steen, A. F. W., Norenberg, J. P., van Gaalen, K., Bernsen, M. R., de Jong, M., & der Heiden, K. V. (2021) · Figshare · doi:10.6084/m9.figshare.14234815
Handula, M., Beekman, S., Konijnenberg, M., Stuurman, D. C., de Ridder, C., Bruchertseifer, F., Morgenstern, A., Denkova, A. G., de Blois, E., & Seimbille, Y. (2023) · Figshare · doi:10.6084/m9.figshare.23612575
Dearling, J. L. J., van Dam, E. M., Harris, M. J., & Packard, A. B. (2021) · Figshare · doi:10.6084/m9.figshare.14121668
Xia, Y., Zeng, C., Zhao, Y., Zhang, X., Li, Z., & Chen, Y. (2020) · Figshare · doi:10.6084/m9.figshare.12135258
Gil-Santos, S., Calheiros, R., Oliveira, J., Santos, R. M. G., & Souteiro, P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1729451
AI Applications in Nuclear Medicine and Hybrid Imaging
Livieratos, L., Trauernicht, C. J., & Champendal, M. (2026) · Springer eBooks · doi:10.1007/978-3-032-05080-9_10
Hubalewska-Dydejczyk, A., Decristoforo, C., Mikołajczak, R., Kolenc, P., Opalińska, M., Garnuszek, P., Skórkiewicz, K., Głowa, B., Trofimiuk–Müldner, M., Studen, A., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270347
Développement d'analogues urotensinergiques radiomarqués pour l'imagerie de tumeurs solides
Poret, B. (2018) · theses.fr (ABES) · doi:10.70675/bbffea07z6c9cz43f4zb871z7b6df9df9cd2
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions—Part 1
Somma, C., Zimmermann, R., Gericke, G., & Herrmann, K. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270855
McCutcheon, C., Lawrence, Z., James, M., Palluccio, T. D., Chowdhury, M., Singh, P. K., Orcutt, K. D., & Patel, S. (2026) · Molecular Imaging and Biology · doi:10.1007/s11307-026-02113-9
Guth, M. A. S. (2026) · Clinical nuclear medicine open. · doi:10.1097/nm9.0000000000000092
Schmidt, F., Lider, S.-M., McDougall, L., Eigler, C., Bernhardt, P., Mushaweh, A., Bauman, A., Fani, M., Christ, E., & Wild, D. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-08122-8
Kuang, X., Zhang, L., Tian, J., Zhang, R., Zhang, Y., & Luo, L. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01822
Metadata
- Authors
- Fani, M., Nicolas, G. P., & Wild, D.
- Affiliations
- University Hospital of Basel (CH)
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-09
- Volume
- 58
- Issue
- Supplement 2
- Pages
- 61S-66S
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2752482655
- Cited by
- 274
- References
- 24
- Citations by year
- 2026: 15 · 2025: 31 · 2024: 27 · 2023: 38 · 2022: 21 · 2021: 36 · 2020: 39 · 2019: 37 · 2018: 24 · 2017: 5
- FWCI
- 22.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- somatostatin receptor antagonists, somatostatin receptor scintigraphy, peptide receptor radionuclide therapy, neuroendocrine tumors, theranostics, 68Ga-DOTATOC, 177Lu-DOTATOC, receptor internalization, somatostatin receptor 2, radiolabeled somatostatin analogs
- MeSH terms
- Animals, Diagnostic Imaging, Humans, Isotope Labeling, Receptors, Somatostatin, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
